New drug cocktail targets tough lung cancer
NCT ID NCT03202940
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This study tests a combination of two oral drugs, alectinib and cobimetinib, in people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see if the combo can shrink tumors. Sixteen adults with stage IV disease are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts general Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alectinib and cobimetinib
What this could lead to
If this combination works, it could offer a new treatment option for people with ALK-positive lung cancer whose disease has stopped responding to standard therapy.
What could go wrong
This is an early-phase trial with only 16 participants, so results may not apply to all patients. The combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.